{"downloaded": true, "htmlmade": false, "full": {"id": "30262852", "source": "MED", "pmid": "30262852", "pmcid": "PMC6160434", "fullTextIdList": {"fullTextId": "PMC6160434"}, "doi": "10.1038/s41598-018-32659-w", "title": "Maintenance DFMO Increases Survival in High Risk Neuroblastoma.", "authorString": "Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM.", "authorList": {"author": [{"fullName": "Sholler GLS", "firstName": "Giselle L Saulnier", "lastName": "Sholler", "initials": "GLS", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA. giselle.sholler@helendevoschildrens.org."}, {"affiliation": "Michigan State University College of Human Medicine, East Lansing, USA. giselle.sholler@helendevoschildrens.org."}]}}, {"fullName": "Ferguson W", "firstName": "William", "lastName": "Ferguson", "initials": "W", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Saint Louis University School of Medicine, St. Louis, USA."}}}, {"fullName": "Bergendahl G", "firstName": "Genevieve", "lastName": "Bergendahl", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Bond JP", "firstName": "Jeffrey P", "lastName": "Bond", "initials": "JP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Neville K", "firstName": "Kathleen", "lastName": "Neville", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Arkansas Children's Hospital, Little Rock, USA."}}}, {"fullName": "Eslin D", "firstName": "Don", "lastName": "Eslin", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Arnold Palmer Hospital for Children, Orlando, USA."}}}, {"fullName": "Brown V", "firstName": "Valerie", "lastName": "Brown", "initials": "V", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Penn State Health Children's Hospital at the Penn State Milton S. Hershey Medical Center, Hershey, USA."}}}, {"fullName": "Roberts W", "firstName": "William", "lastName": "Roberts", "initials": "W", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Rady Children's Hospital San Diego and UC San Diego School of Medicine, San Diego, USA."}}}, {"fullName": "Wada RK", "firstName": "Randal K", "lastName": "Wada", "initials": "RK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Kapiolani Medical Center for Women and Children, Honolulu, USA."}}}, {"fullName": "Oesterheld J", "firstName": "Javier", "lastName": "Oesterheld", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Levine Children's Hospital, Charlotte, USA."}}}, {"fullName": "Mitchell D", "firstName": "Deanna", "lastName": "Mitchell", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Foley J", "firstName": "Jessica", "lastName": "Foley", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Parikh NS", "firstName": "Nehal S", "lastName": "Parikh", "initials": "NS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Connecticut Children's Medical Center, Hartford, USA."}}}, {"fullName": "Eshun F", "firstName": "Francis", "lastName": "Eshun", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Phoenix Children's Hospital, Phoenix, USA."}}}, {"fullName": "Zage P", "firstName": "Peter", "lastName": "Zage", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Rady Children's Hospital San Diego and UC San Diego School of Medicine, San Diego, USA."}}}, {"fullName": "Rawwas J", "firstName": "Jawhar", "lastName": "Rawwas", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Children's Hospitals and Clinics of Minnesota, Minnesota, USA."}}}, {"fullName": "Sencer S", "firstName": "Susan", "lastName": "Sencer", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Children's Hospitals and Clinics of Minnesota, Minnesota, USA."}}}, {"fullName": "Pankiewicz D", "firstName": "Debra", "lastName": "Pankiewicz", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Quinn M", "firstName": "Monique", "lastName": "Quinn", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Rich M", "firstName": "Maria", "lastName": "Rich", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Junewick J", "firstName": "Joseph", "lastName": "Junewick", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA."}}}, {"fullName": "Kraveka JM", "firstName": "Jacqueline M", "lastName": "Kraveka", "initials": "JM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Medical University of South Carolina, Charleston, USA."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "1", "volume": "8", "journalIssueId": "2722578", "dateOfPublication": "2018 Sep", "monthOfPublication": "9", "yearOfPublication": "2018", "printPublicationDate": "2018-09-01", "journal": {"title": "Scientific reports", "ISOAbbreviation": "Sci Rep", "medlineAbbreviation": "Sci Rep", "NLMid": "101563288", "ISSN": "2045-2322", "ESSN": "2045-2322"}}, "pubYear": "2018", "pageInfo": "14445", "abstractText": "High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750\u2009\u00b1\u2009250\u2009mg/m<sup>2</sup> twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (\u00b14%) and OS 97% (\u00b12%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (\u00b18%) and OS 84% (\u00b16%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB.", "affiliation": "Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, USA. giselle.sholler@helendevoschildrens.org.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Neuroblastoma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Eflornithine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Child, Preschool"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "Maintenance Chemotherapy"}]}, "chemicalList": {"chemical": {"name": "Eflornithine", "registryNumber": "ZQN1G5V6SR"}}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41598-018-32659-w"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6160434"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6160434?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "14", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": ["refsnp", "nct"]}, "dateOfCompletion": "2019-10-23", "dateOfCreation": "2018-09-29", "firstIndexDate": "2018-09-29", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2019-10-23", "electronicPublicationDate": "2018-09-27", "firstPublicationDate": "2018-09-27"}, "htmllinks": "https://europepmc.org/articles/PMC6160434", "abstract": "High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750\u2009\u00b1\u2009250\u2009mg/m<sup>2</sup> twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (\u00b14%) and OS 97% (\u00b12%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (\u00b18%) and OS 84% (\u00b16%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB.", "pdflinks": "https://europepmc.org/articles/PMC6160434?pdf=render", "journaltitle": "Scientific reports", "authorinfo": ["Sholler GLS", "Ferguson W", "Bergendahl G", "Bond JP", "Neville K", "Eslin D", "Brown V", "Roberts W", "Wada RK", "Oesterheld J", "Mitchell D", "Foley J", "Parikh NS", "Eshun F", "Zage P", "Rawwas J", "Sencer S", "Pankiewicz D", "Quinn M", "Rich M", "Junewick J", "Kraveka JM"], "title": "Maintenance DFMO Increases Survival in High Risk Neuroblastoma."}